Clinical translation of stem cell therapy in traumatic brain injury: The potential of encapsulated mesenchymal cell biodelivery of glucagon-like peptide-1

Dialogues in Clinical Neuroscience

Volumn 13, Issue 3, 2011, Pages 279-286

  Heile, Anna ^a   Brinker, Thomas ^b  

^a INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

Inflammation; Mesenchymal stem cell; Neuroprotection; Translational research; Traumatic brain injury

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BROXURIDINE; COFILIN; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INTERLEUKIN 6; MICROTUBULE ASSOCIATED PROTEIN 2; PRESENILIN 1; PRESENILIN 2; PROPIDIUM IODIDE; SYNAPSIN I;

ALZHEIMER DISEASE; ARTICLE; BARTHEL INDEX; BRAIN HEMORRHAGE; CD4+ T LYMPHOCYTE; CELL DEATH; CELL DIFFERENTIATION; CELL ENCAPSULATION; CELL MIGRATION; CELL PROLIFERATION; CORD BLOOD STEM CELL TRANSPLANTATION; DENTATE GYRUS; ENGRAFTMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOFLUORESCENCE TEST; LOCOMOTION; MESENCHYMAL STEM CELL; MICROENCAPSULATION; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLURIPOTENT STEM CELL; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TRANSLATIONAL RESEARCH; TRAUMATIC BRAIN INJURY; WISTAR RAT; ANIMAL; BIOLOGICAL THERAPY; BRAIN INJURY; GENETIC TRANSFECTION; MESENCHYMAL STEM CELL TRANSPLANTATION; METHODOLOGY; REVIEW;

ANIMALS; BRAIN INJURIES; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; TISSUE THERAPY; TRANSFECTION; TRANSLATIONAL RESEARCH;

EID: 82255195941     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Hyder AA, Wunderlich CA, Puvanachandra P, Gururaj G, Kobusingye OC. The impact of traumatic brain injuries: a global perspective. Neuro Rehab. 2007;22:341-353.
2. Rehabilitation of persons with traumatic brain injury. NIH. Consens Statement. 1998;16:1-41.
3. Erceg S, Ronaghi M, Stojkovic M. Human embryonic stem cell differentiation toward regional specific neural precursors. Stem Ceils. 2009;27:78-87.
4. Li JY, Christophersen NS, Hall V, Soulet D, Brundin P. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci. 2008;31:146-153.
5. Cattaneo E, McKay R. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor. Nature. 1990;347:762-765.
6. Hsu YC, Lee DC, Chiu IM. Neural stem cells, neural progenitors, and neurotrophic factors. CellTranspl. 2007;16:133-150.
7. Jensen JB, Parmar M. Strengths and limitations of the neurosphere culture system. Mol Neurobiol. 2006;34:153-161.
8. Bliss T, Guzman R, Daadi M, Steinberg GK. Cell transplantation therapy for stroke. Stroke. 2007;38:817-826.
9. Longhi L, Zanier ER, Royo N, Stocchetti N, Mcintosh TK. Stem cell transplantation as a therapeutic strategy for traumatic brain injury. Transpl Immunol. 2005;15:143-148.
10. Chen J, Li Y, Wang L, Lu M, Zhang X, Chopp M. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci. 2001;189:49-57.
11. Ohtaki H, Ylostalo JH, Foraker JE, et al. Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses. Proc Natl Acad Sci USA. 2008;105:14638-14643.
12. Sarnowska A, Braun H, Sauerzweig S, Reymann KG. The neuroprotective effect of bone marrow stem cells is not dependent on direct cell contact with hypoxic injured tissue. Exp Neurol. 2009;215:317-327.
13. Savitz SI. Introduction to cellular therapy: the next frontier for stroke therapeutics. Stroke. 2009;40:S141-S142.
14. Lundberg J, Le Blanc K, Sôderman M, Andersson T, Holmin S. Endovascular transplantation of stem cells to the injured rat CNS. Neuroradiology. 2009;51:661-667.
15. Kuh SU, Cho YE, Yoon DH, Kim KN, Ha Y. Functional recovery after human umbilical cord blood cells transplantation with brain-derived neutrophic factor into the spinal cord injured rat. Acta Neurochir. 2005;147:985-992.
16. Salazar DL, Uchida N, Harriers FP, Cummings BJ, Anderson AJ. Human neural stem cells differentiate and promote locomotor recovery in an early chronic spinal cord injury NOD-scid mouse model. PLoS One. 2010;5:e12272.
17. Walker PA, Harting MT, Jimenez F, et al. Direct intrathecal implantation of mesenchymal stromal cells leads to enhanced neuroprotection via an NFkappaB mediated increase in Interleukin 6 (IL-6) production. Stem Cells Devel. 2010;19:867-876.
18. Benveniste EN. Cytokine actions in the central nervous system. Cytokine Growth Factor Rev. 1998;9:259-275.
19. Glazova M, Pak ES, Moretto J, Mollis S, Brewer KL, Murashov AK. Predifferentiated embryonic stem cells promote neuronal regeneration by cross-coupling of BDNF and IL-6 signaling pathways in the host issue. J Neurotraurna. 2009;26:1029-1042.
20. Popovich PG, Hickey WF. Bone marrow chimeric rats reveal the unique distribution of resident and recruited macrophages in the contused rat spinal cord. J Neuropathol Exp Neurol. 2001;60:676-685.
21. Ankeny DP, Popovich PG. Mechanisms and implications of adaptive immune responses after traumatic spinal cord injury. Neuroscience. 2009;158:1112-1121.
22. Hailer NP. Immunosuppression after traumatic or ischemic CNS damage: it is neuroprotective and illuminates the role of microglial cells. Prog Neurobiol. 2008;84:211-233.
23. Walker PA, Shah SK, Jimenez F, et al. Intravenous multipotent adult progenitor cell therapy for traumatic brain injury:preserving the blood brain barrier via an interaction with splenocytes. Exp Neurol. 2010;225:341-352.
24. Németh K, Leelahavanichkul A, Yuen PS, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E -dependent reprogramming of host macrophages to increase their interleukin-10 production. Wat Med. 2009;15:42-49.
25. Harting MT, Jimenez F, Xue H, et al. Intravenous mesenchymal stem cell therapy for traumatic brain injury. J. Neurosurg. 2009;110:1189-1197.
26. Boockvar JA, Schouten J, Royo N, et al. Experimental traumatic brain injury modulates the survival, migration, and terminal phenotype of transplanted epidermal growth factor receptor-activated neural stem cells. Neurosurgery. 2005; 56:163-171.
27. Cao M, Zhang YP, Howard RM, Walters WM, Tsoulfas P, Whittemore SR. Pluripotent stem cells engrafted into the normal or lesioned adult rat spinal cord are restricted to a glial lineage. Exp Neurol. 2001;167:48-58.
28. Zheng XS, Yang XF, Liu WG, Pan DS, Hu WW, Li G. Transplantation of neural stem cells into the traumatized brain induces lymphocyte infiltration. Brain inj. 2007;21:275-278.
29. Tseng JL, Aebischer P. Encapsulated neural transplants. Prog Brain Res. 2000;127:189-202.
30. Murua A, Portera A, Drive G, Hernandez RM, de Castro M, Pedraz JL. Cell microencapsulation technology:towards clinical application. J Control Release. 2008;132:76-83.
31. Soon-Shiong P, Heintz RE, Merideth N, et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet. 1994;343:950-951.
32. Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med. 1996;2:696-699.
33. Zurn AD, Henry H, Schluep M, et al. Evaluation of an intrathecal immune response in amyotrophic lateral sclerosis patients implanted with encapsulated genetically engineered xenogeneic cells. Cell Transpl. 2000;9:471-484.
34. Buchser E, Goddard M, Heyd B, et al. Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience. Anesthesiology. 1996;85:1005-1012.
35. Bachoud-Levi AC, Maison P, Bartolomeo P, et al. Retest effects and cognitive decline in longitudinal follow-up of patients with early HD. Neurology. 2001;56:1052-1058.
36. Bjerkvig R, Read TA, Vajkoczy P, et al. Cell therapy using encapsulated cells producing endostatin. Acta Neurochir Suppl. 2003;88:137-141.
37. Read TA, Stensvaag V, Vindenes H, Ulvestad E, Bjerkvig R, Thorsen F. Cells encapsulated in alginates potential system for delivery of recombinant proteins to malignant brain tumours. Int J Dev Neurosci. 1999;17:653-663.
38. Visted T, Lund-Johansen M. Progress and challenges for cell encapsulation in brain tumour therapy. Exp Opin Biol Ther. 2003;3:551-561.
39. Heile AM, Wallrapp C, Klinge PM, et al. Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury. Neurosci Lett. 2009;463:176-181.
40. Drucker DJ. Gut adaptation and the glucagon-like peptides. Gut. 2002;50:428-435.
41. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide1 in the mouse. Endocrinology. 1994;134:2156-2164.
42. Gilman CP, Perry T, Furukawa K, Grieg NH, Egan JM, Mattson MP. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem. 2003; 87:1137-1144.
43. Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300:958-966.
44. Perry T, Lahiri DK, Sambamurti K, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci Res. 2003;72:603-612.
45. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173-1179.
46. Hoist JJ. Glucagon-like peptide-1:from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia. 2006;49:253-260.
47. Simonsen JL, Rosada C, Serakinci N, et al. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol. 2002;20:592-596.
48. Klinge PM, Harmening K, Kassem M, et al. Encapsulated native and glucagon-like peptide-1 transfected human mesenchymal stem cells in a transgenic mouse model of Alzheimer's disease. Neurosci Lett. 2011;497:6-10.
49. GLP-1 CeMBeadsâ for the Treatment of Stroke Patients With Spaceoccupying Intracerebral Hemorrhage. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01 298830 term=NCT01298830&rank=1. Accessed April 14 2011
50. Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer's disease? Pharmacogenomics J. 2006;6:8-15.
51. Thorne RG, Frey WH. Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet. 2001;40:907-946.
52. Aird RB A study of intrathecal, cerebrospinal fluid-to-brain exchange. Exp Neurol. 1984;86:342-358.
53. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. Drug delivery to damaged brain. Brain Res Brain Res Rev. 2001;38:140-148.
54. Bloch J, Bachoud-Levi AC, Deglon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther. 2004;15:968-975.
55. Schwenter F, Schneider BL, Pralong WF, Deglon N, Aebischer P. Survival of encapsulated human primary fibroblasts and erythropoietin expression under xenogeneic conditions. Hum Gene Ther. 2004;15:669-680.
56. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci USA. 2006;103:3896-3901.
57. Mittoux V, Joseph JM, Conde F, et al. Restoration of cognitive and motor functions by ciliary neurotrophic factor in a primate model of Huntington's disease. Hum Gene Ther. 2000;11:1177-1187.